Back to search results

ENHANCE Trial: Exercise Training During Immunotherapy for Lung Cancer

This study, called the ENHANCE Trial, is looking at how different types of exercise affect people with advanced non-small cell lung cancer who are receiving immunotherapy (a treatment that uses your body's own immune system to fight cancer). You would be randomly assigned to one of three groups: High-Intensity Interval Training (HIIT), Moderate-Intensity Continuous Training (MICT), or usual care. The exercise groups will do home-based, virtually supervised workouts for 12 weeks. The main goal is to see how many participants complete the exercise sessions. To join, you need to be at least 18 years old, have non-small cell lung cancer, be on immunotherapy for at least one month, and have your doctor's approval to exercise. The study is currently recruiting about 30 participants.

Study design
This is a pilot randomized controlled study with three groups, aiming to enroll 30 participants. It compares high-intensity exercise, moderate-intensity exercise, and usual care.
What's involved
Participants in the exercise groups will do virtually supervised home-based exercise three times a week for 12 weeks. The usual care group will maintain their normal activity for 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured up to 14 weeks, indicating follow-up during and shortly after the intervention period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06026111

Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial

Recruiting
NAAges 18+InterventionalSupportive care
Dana-Farber Cancer Institute
~30 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:High-Intensity Interval Training (HIIT)Moderate-Intensity Continuous Training (MICT)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of Participants completing the exercise intervention sessions
Measured over Up to 14 weeks

Conditions

Lung Cancer

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Christina Dieli-Conwright, PhD, MPH · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute

Who to contact

Christina Dieli-Conwright, PhD, MPH
[email protected]
617-582-8321
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years.
Histologically diagnosed with non-small cell lung cancer (NSCLC).
Having been receiving immunotherapy for at least one month with a plan to continue for at least 12 weeks prospectively at the time of recruitment.
Medical clearance to perform exercise intervention and testing by their treating oncologist.
No uncontrolled medical conditions that could be exacerbated with exercise (e.g., uncontrolled hypertension or diabetes).
Ability to communicate and complete written forms in English.
Participate in less than or equal to 60 minutes of moderate-to-vigorous aerobic exercise per week over the past month.
Ability to understand and the willingness to sign informed consent prior to any study-related procedures.
Willing to travel to DFCI for necessary data collection.

Exclusion

Participate in more than 60 minutes of moderate-to-vigorous aerobic exercise per week over the past month. This study targets insufficiently active persons to assess the effect of the described exercise intervention, where additional exercise done regularly will contaminate the intervention outcomes.
Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities may develop unexpected adverse events from exercise. For the purpose of patients' safety, as well as because part of this study involves remote, home-based exercise where close supervision is not possible, patients with unstable medical conditions are excluded.
Subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.
Development of second malignancy (except for basal cell carcinoma or squamous cell carcinoma of the skin) that requires concurrent treatment, which would interfere with this study.

What this trial measures

  • Proportion of Participants completing the exercise intervention sessionsUp to 14 weeks

    The primary outcome is feasibility and will be assessed by the proportion of enrolled participants completing the exercise intervention sessions with \>/=70% completion considered feasible.